The omicron variant of the coronavirus is spreading. Initial laboratory studies suggest that it can bypass the immune protection people have acquired through vaccination or coronavirus infection better than previous mutants.
Now Biontech and Pfizer have published first, preliminary results on the efficacy of their vaccine against Omikron. According to the results, double-vaccinated individuals have significantly lower neutralisation titres against Omikron - that is, they are significantly less protected against this variant than against other coronavirus mutants.
However, the data also showed that a third dose increased the amount of neutralising antibodies by 25-fold compared to two doses, the companies said. "These initial data suggest that a booster vaccination can still provide sufficient protection against disease of any severity caused by the omicron variant," Biontech founder Ugur Sahin said, according to the statement.
Press release:
Pfizer and BioNTech Provide Update on Omicron Variant
But remember: a booster helps to protect you from Omicron – but it won’t end the pandemic.